- ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
- Next-gen CAR-T player steps on the gas with a $111M boost and a positive glimpse at early data
- Secondary patents prove to be key in biosimilar blocking strategies, researchers find
- Amgen Ventures Invests in TileDB to Advance Their Universal Database
- AstraZeneca’s MCL-1 cancer drug put on hold after flagging a safety issue — 2 years after Amgen axed rival drug
- ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
- Deep 6 AI Announces Substantial Expansion of its Innovative AI-Based Clinical Trial Acceleration Software and Research Ecosystem
- The U.S. is more racially diverse than ever. Will people of color unify politically?
- Teva temporarily padlocks a plant after FDA cites it for contamination
- A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future Tmod™ CAR T Therapy
Copyright © 2021 Biotech Networks, LLC
